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OBJECTIVES: The aim of this study was to investigate the frequency of frailty and the association of vitamin D
levels and the frailty phenotype among non-geriatric dialysis patients.
METHOD: Seventy-four stable, chronic hemodialysis patients from the hemodialysis unit of the hospital were
enrolled in the study. The patients’ medical histories and laboratory findings were obtained from the medical
records of the dialysis unit. Serum parathyroid hormone and 25-hydroxy vitamin D levels were determined using
chemiluminometric immunoassays. Frailty was defined by Fried et al. as a phenotype; shrinking, weakness, self-
reported exhaustion, decreased activity and slowed walking speed were evaluated.
RESULTS: Forty-one (55%) of the patients were males. The patients were divided into 3 groups according to
frailty scores: 39 (53%) patients were frail, 6 (8%) patients were intermediately frail, and 28 (39%) patients were
normal. Significant differences were found for 25-hydroxy vitamin D and hemoglobin levels among the groups;
however, no differences were observed in body mass index, comorbidities, sex, marital status, education, disease
and dialysis durations, or parathyroid hormone, creatinine, serum calcium, phosphorus, and potassium levels.
CONCLUSIONS: Weakness and slowness are serious outcomes of both vitamin D deficiency and frailty, and
vitamin D deficiency has been associated with increased risks of decreased physical activity, falls, fractures and
death in postmenopausal women and older men. Although studies on frailty have focused on older adults,
growing evidence indicates that the frailty phenotype is becoming a factor associated with poor health
outcomes in non-geriatric populations with chronic disease.
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’ INTRODUCTION
The prevalence of frailty syndrome, which is defined as a bio-
logical state of increased susceptibility to adverse health condi-
tions, has recently increased from 6.5% to 65%, which is closely
related to the aging trends of populations worldwide (1-3).
Chronic kidney disease (CKD) is a major health problem,
with a prevalence of 23.4% to 35.8% in persons aged 64 years
or older, and affects over 2 million people worldwide (1).
CKD increases the risk of cardiovascular disease, frailty
and disability (4,5). Although the relationship between CKD
and frailty is not completely understood, dysfunction of
various systems, including hemoglobin, Interleukin 6 (IL-6),
insulin-like growth factor 1 (IGF-1), dehydroepiandrosterone
S (DHEA-S), hemoglobuline A1c (Hb A1c), 25-hydroxy
vitamin D, vitamin B12, and carotenoids in frailty suggests
common pathological pathways for both disorders (1,6).
Frail individuals experience important physical and
mental impairments that interfere with activities of daily
living (7). The presentation of frailty is variable and may
include low physical activity levels and fewer social con-
nections (7,8).
Weakness and slowness are two constituents of frailty that
are potential outcomes of vitamin D deficiency. Low vitamin
D levels have been associated with increased risks of decrea-
sed physical activity, falls, fractures and death in postmeno-
pausal women and older men. Vitamin D deficiency is relatively
common in the general population and is also a particular
risk for patients with CKD. Reduced sun exposure, impaired
production of 25-hydroxy vitamin D, and reduced dietary
intake are factors that may affect vitamin D levels, apart from
the patient’s renal function (9).
Although studies on frailty have focused on older adults,
growing evidence indicates that the frailty phenotype is
becoming a factor associated with poor health outcomes in
non-geriatric populations with chronic disease (10-15).
This study aimed to investigate the frequency of frailty
and the association between vitamin D levels and the frailty
phenotype among non-geriatric dialysis patients.DOI: 10.6061/clinics/2018/e116
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’ METHODS
This cross-sectional study was conducted in an outpatient
hemodialysis clinic between October 1 and November 1,
2016. All stable CKD subjects between 18 and 65 years of age
who had received hemodialysis for at least 12 months were
invited to participate in the study. Subjects who had received
hemodialysis for less than 12 months, had arteriovenous
fistulas in both arms, had dementia, were institutionalized
for renal or other health problems, or were in preparation for
kidney transplantation were excluded from the study.
Hemodialysis therapy was performed three times per week,
with each session lasting approximately 4 hours. A standard
heparin infusion was administered intravenously before each
session, and an erythropoietin dose of 75-150 U/kg/week
was given following the session to adjust hemoglobin levels
if necessary.
Patients’ medical histories and laboratory findings were
obtained from the medical records of the dialysis unit. The
most recent results of the monthly controlled serum calcium,
phosphate, potassium, albumin, hemoglobin, creatinine and
alkaline phosphatase levels were recorded. Serum samples
were analyzed in an on-site biochemistry laboratory using
standard auto-analyzer techniques. Serum intact parathyroid
hormone levels were determined using chemiluminometric
immunoassays.
Serum 25-hydroxy vitamin D levels were measured using a
radioimmunoassay kit (Minividas Biomeriux, France). Vitamin
D levels were categorized as risk of deficiency, o12 ng/mL;
risk of inadequacy, 12-19 ng/mL; and sufficiency, 20-50 ng/
mL (16).
Frailty syndrome was defined by Fried et al. as the pre-
sence of at least three of the five phenotypic components,
including shrinking, weakness, self-reported exhaustion,
decreased activity and slowed walking speed (17). Shrinking
was defined as self-reported unintentional weight loss. Patients
were questioned about unintentionally losing more than 4.5 kg
(of dry weight) during the past year. Weakness was defined as
the lowest quintile of the grip strength adjusted for age, sex and
BMI, as reported by Massy-Westropp. Handgrip strength was
measured 3 times on the non-fistulated side in standing posi-
tion. A dynamometer (JAMAR Technologies, Inc. Hatfield, PA.)
was held at thigh level, and the patient was asked to squeeze
the instrument as hard as possible for 3 seconds. The average
of the three measurements was used in the analysis. Grip
strengths were evaluated based on age- and sex-adjusted values
described in the study of Massy-Westropp NM et al. (18).
Self-reported exhaustion was defined as a feeling of gene-
ralized weakness or lack of energy in the past 12 months.
The level of activity was evaluated with the Turkish
version of The International Physical Activity Questionnaire
(IPAQ), which is a self-administered form consisting of seven
questions and provides information on sitting, walking,
moderate-intensity activities, and the duration of vigorous
activity in the last seven days. Physical activity levels were
classified as adequate physical activity (3000 MET-min/week),
low physical activity (600-3000 MET-min/week) and physi-
cally inactive (o600 MET-min/week) (19). Slowed walking was
evaluated with a 10-meter walk test (10 MWT). A 14-meter-
long straight line was drawn, and 2 meters from either end of
the line were marked. The test was performed 2 hours before
the dialysis session. The time required to walk the 10 meters
was recorded, and the average value was calculated after
two evaluations (20). Each component of frailty was assigned
1 point when present, and the frailty score was calculated as
the sum of the component scores (range 0-5). According to the
frailty scores, the subjects were categorized as not frail (score
0-1), intermediately frail (score 2), and frail (score 3-5) (13). The
study protocol was approved by the local ethics committee,
and written informed consent was obtained from all patients.
Statistical Analysis
For the statistical analysis, SPSS for Windows Version 16
was used to assess study data. Descriptive statistics are
provided as the average and standard deviation; the Pearson
correlation coefficient was used to determine correlations,
and ANOVA was used to evaluate comparisons. The results
were assessed using a 95 % confidence interval with a sig-
nificance level of p o 0.05.
’ RESULTS
A total of 74 hemodialysis patients, 33 (44.6%) of whom
were male, aged between 18 and 65 years (mean age±
standard deviation, 50.91±10.14 years), were included in the
study group.
The mean BMI was 24.89±5.23 kg/m2, and the mean
disease duration was 9.9±7.2 years. The demographic and
clinical characteristics of the patients are summarized in
Table 1 and Table 2.
The mean gait speed and IPAQ scores were 1.2±0.67 m/sec
and 793.15±832.95 MET/week, respectively. Thirty-eight (51%)
of the patients had poor endurance, and 28 (38%) patients
reported unintentional weight loss during the past year (Table 3).
Table 1 - Demographic Characteristics of the Patients.
Patients (n=74)
Age (yr; mean ± SD 50.91±10.14
Sex
Female (n/%) 33 (45%)
Male (n/%) 41 (55%)
BMI (kg/m2; mean ± SD) 24.89±5.23
Married (n/%) 64 (86%)
Employed (n/%) 13 (18%)
High school graduate (n/%) 2 (3%)
Current smoker (n/%) 14 (19%)
Descriptive statistics were used.
Table 2 - Clinical Parameters of the Patients.
Patients (n=74)
Disease duration (yr; mean ± SD) 9.9±7.2
Dialysis duration (yr; mean ± SD) 8.9±7.1
Comorbidities: Diabetes (n/%) 5 (7%)
Hypertension (n/%) 17 (27%)
Coronary arterial disease (n/%) 23 (31%)
Cerebrovascular disease (n/% 3 (4%)
Peripheral arterial disease (n/%) 11 (15%)
Cancer (n/%) 0 (0 %)
Serum creatinine 6.3±2.2
Serum albumin (mg/dL; mean ± SD) 4.04±0.41
Hemoglobin (g/dL; mean ± SD) 7.04±2.18
Serum potassium 5.2±1.02
Serum calcium 9.6±0.8
Serum phosphorus 5.5±1.54
Alkaline phosphatase 76±51
25 (OH) Vitamin D (ng/dL; mean ± SD) 13.93±8.64
Parathyroid hormone (pg/dL; mean ± SD) 612.16±519.24
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A weak positive correlation was observed between the
frailty score and age (r=0.244; p=0.038).
A negative correlation was found between the frailty score
and serum hemoglobin, serum albumin and 25-hydroxy
vitamin D levels (r=-0.336, p=0.004; r=-0.263, p=0.025; r=
-0.363, p=0.002, respectively). No correlation was observed
between the frailty score and BMI, comorbidities, sex, disease
and dialysis duration, and parathyroid hormone, creatinine,
serum calcium, phosphorus, or potassium levels (Table 4).
The patients were divided into 3 groups according to
frailty scores: 39 (53%) patients were frail, 6 (8%) patients
were intermediately frail, and 28 (39%) patients were normal.
Significant differences were found among groups for 25-
hydroxy vitamin D and hemoglobin levels (p=0.037, p=0.005,
respectively); however, no differences were observed in
BMI, comorbidities, sex, disease and dialysis duration, and
parathyroid hormone, creatinine, serum calcium, phosphorus,
and potassium levels (Table 5).
’ DISCUSSION
Frail and intermediately frail phenotypes were detected in
53% and 18% of CKD patients, respectively, in the study group.
A significant positive correlation was found between the frailty
score and age. While frailty was associated with low albumin,
hemoglobin and vitamin D levels in this study, the duration of
CKD or dialysis treatment and parathyroid hormone levels
were not correlated with frailty. The vitamin D and hemoglobin
levels were significantly lower in frail subjects.
In a systematic review, the prevalence of frailty ranged
between 7% and 42% in pre-dialysis CKD patients (18). Van
Munster et al. reported the prevalence of frailty as 44% and
28% in CKD patients older and younger than 65 years of
age, respectively (21). The prevalence of frailty increases with
age; however, in dialysis patients, frailty may also develop
independent of age (13,22-24). In this regard, the detection of
frailty in 53 % of the non-geriatric subjects and the correla-
tion between the frailty score and age are noteworthy.
Frailty is more common among patients with comorbid-
ities. Cardiovascular disease, diabetes, stroke, and low albumin
concentrations were shown to be significantly associated
with frailty in previous studies (25,26). The results of the
current study also indicate a correlation between low albu-
min and hemoglobin levels.
Recent reports suggest that vitamin D deficiency is
associated with increased mortality in dialysis patients
(27-29). Considering the relationship between frailty and
increased mortality, it is relevant to investigate the associa-
tion between vitamin D levels and frailty. A cohort study on
25-hydoxy vitamin D levels and frailty in elderly women
reported that the odds ratio for frailty was higher for those
Table 3 - Frailty Phenotypes of the Patients.
Patients (n=74)
Weakness (grip strength) (mean ± SD) 32.66±24.2
Slowness (gait speed m/s) (mean ± SD) 1.2±0.67
Low physical activity (IPAQ scores; MET/week)
(mean ± SD)
793.15±832.95
Poor endurance (exhaustion) (n/%) 38 (51%)
Shrinkage (unintentional weight loss) (n/%) 28 (38%)
Frailty scores Frail (n/%) 39 (53%)
Intermediately frail (n/%) 13 (18%)
Not frail (n/%) 21 (28%)
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with lower and higher levels of vitamin D at baseline and
that non-frail women with low vitamin D levels at baseline
were more likely to develop frailty or to die (30). Dreschsler
et al. proposed that severe vitamin D deficiency was asso-
ciated with increased mortality in dialysis patients, and the
clinical consequences of vitamin D levels were related to
parathyroid hormone levels (31). Vitamin D levels were
significantly lower in the frail subjects than in the non-frail
subjects in this study group. Although a (negative) correla-
tion between frailty and vitamin D levels was detected,
no association was found for parathyroid hormone levels in
our study.
Emotional and economic burdens associated with frailty
necessitate the prevention or reversal of this process (32).
Regular exercise may help maintain or restore functional
capacity and independence in the elderly (33) and has been
shown to be preventive against frailty and disability in CKD
patients. The consequences of decreased physical activity
may be reversed, and the survival rate may be improved
with physical exercise in both elderly individuals and CKD
patients. Frailty is implicated as a common pathway to
disability in both aging and CKD, which can be prevented
with a multidisciplinary approach, wherein physical exercise
is essential (34).
One of the strong aspects of this study is the documenta-
tion of the high prevalence of frailty in a limited non-geriatric
dialysis patient group. Nevertheless, there are several limi-
tations associated with this study. First, a cross-sectional
study design has its own limitations, including response and
recall biases and the difficulty of establishing a temporal
relationship between the exposures and outcomes. Use of
the Fried phenotype may be considered another limitation.
Although the frailty phenotype described by Fried et al. has
been widely used in previous studies, concerns exist about
its efficiency in evaluating the severity of frailty in popula-
tions with a high prevalence of frailty (2).
In conclusion, it is important to prevent early-onset dis-
ability in end-stage renal disease, which may be accelerated
by frailty in this patient population, which includes indi-
viduals who already carry a high risk of morbidity and
mortality. The constituents of frailty are also potential con-
sequences of vitamin D deficiency, and lower vitamin D
levels have been associated with decreased physical perfor-
mance. It is necessary to identify the underlying factors
leading to frailty and their effects on general health and
quality of life in CKD patients. Long-term follow-up studies
incorporating physical exercise programs will be necessary
to establish a place for dialysis patients as active members
in society.
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